Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of ImmunoCellular Therapeutics, Ltd.
December 12 2013 - 1:40PM
Business Wire
Shareholder rights law firm Johnson & Weaver, LLP has
commenced an investigation into whether certain officers and
directors of ImmunoCellular Therapeutics, Ltd., (Nasdaq: IMUC)
violated state or federal laws.
On December 11, 2013 after the market closed ImmunoCellular
announced that its lead brain cancer drug, ICT-107, did not
increase overall survival in patients diagnosed with glioblastoma
multiforme. The drug did show a statistically significant benefit
to patients in terms of progression-free survival, delaying the
disease's progression by two months.
ImmunoCellular shares are down over 60% in early morning trading
on the announcement, trading as low as $.98 per share.
However, certain officers and directors, including the founder and
Chairman, sold their personally held shares at prices as high as
$3.86 per shares before this news was released.
Johnson & Weaver’s investigation will seek to determine if
investors were previously misled by ImmunoCellular’s officers or
directors concerning ICT-107’s potential.
If you have information that could assist in this investigation,
or if you are a ImmunoCellular shareholder and are interested in
learning more about the investigation or your legal rights and
remedies, please contact Jim Baker
(jimb@johnsonandweaver.com) by email or by phone at
619-230-0063, Ext. 118.
Johnson & Weaver, LLP is a nationally recognized
shareholders’ rights law firm. The firm represents individual and
institutional investors in shareholder derivative and securities
class action lawsuits. For more information about the firm and its
attorneys, please visit http://www.johnsonandweaver.com.
Johnson & Weaver, LLPJim Baker, 619-230-0063 Ext.
118jimb@johnsonandweaver.com
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Mar 2024 to Apr 2024
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Apr 2023 to Apr 2024